SF-539 Xenograft Model

SF-539 xenograft model

The SF-539 cell line (human brain; glial cell neoplasm; gliosarcoma) is used to create the CDX (Cell Line Derived Xenograft) SF-539 xenograft mouse model.  The SF-539 xenograft model enables a platform to test the anti-tumor efficacy of mono- and combination therapies (e.g. temozolomide, PHA-848125, radiotherapy).

Basic study design

  1. SF-539 cells are maintained under conditions of exponential growth.
  2. Each mouse receives a s.c. inoculation in the flank of one of the hind legs containing one million cells.  The 100 microliter injection volume contains matrigel plus SF-539 cells.
  3. The sites are palpated three times weekly till tumors are established.
  4. Tumors are measured (via digital calipers) until an average size of 50-150 mm3 is maintained and then animals are arranged into cage groups.  Injection of all compounds of interest are performed following manufacturer instructions.
  5. Tumors measurements are taken on a daily basis, with accompanying mouse body weights recorded 3 times weekly.
  6. At the end of study, animals are euthanized humanely.  Tissues are collected as defined for the termination of experiment.  All tumors are excised and weighed; digital imaging is available.
  7. Tissues are collected for downstream analysisand are stabilized in RNAlater, snap frozen or prepared for histological analysis.

Get Instant Quote for
SF-539 Xenograft Model

Xenograft animal models are used to assess the effectiveness of drugs against specific types of cancer. New medicines are tested on staged tumor growths that have been engrafted via subcutaneous or orthotopic inoculation in an immunocompromised mouse or rat model. All clinically approved anti-cancer agents have been evaluated with conventional preclinical in vivo models. Xenograft studies can be highly complex, starting with the selection of the appropriate animal model, choice of tumorigenic cell line, administration method, dosing, analysis of tumor growth rates and tumor analysis (histology, mRNA and protein expression levels).

Altogen Labs provides an array of laboratory services using over 30 standard Cell Line Derived Xenograft (CDX) models and over 20 PDX models. Researchers investigating the role of specific proteins or gene products in regulating tumor growth can benefit from development of protein overexpression (genetically engineered to ectopically express proteins, tumor suppressors, or oncogenes) and RNAi cell lines with long term gene silencing. Altogen Labs provides quantitative gene expression analysis of mRNA expression (RT-PCR) and protein expression analysis using the WES system (ProteinSimple).

The dosing of the experimental compound of interest is initiated, for a staged study, when the mean tumor size reaches a specified volume (typically 50-100 mm3). In an unstaged study, the dosing of the compound of interest is initiated immediately after xenografting. Mice are dosed once or twice a day for 28 days (or other desired study duration) via the chosen route of administration. Tumor volume (mm3) is calculated via the “(W x W x L) / 2” formula, where W is tumor width and L is tumor length.

Animal handling and maintenance at the Altogen Labs facility is IACUC-regulated and GLP-compliant. Following acclimation to the vivarium environment, mice are sorted according to body mass. The animals are examined daily for tumor appearance and clinical signs. We provide detailed experimental procedures, health reports and data (all-inclusive report is provided to the client that includes methods, results, discussion and raw data along with statistical analysis). Additional services available include collection of tissue, histology, isolation of total protein or RNA and analysis of gene expression. Our animal facilities have the flexibility to use specialized food or water systems for inducible gene expression systems.

Following options are available for the SF-539 xenograft model:

  • SF-539 Tumor Growth Delay (TGD; latency)
  • SF-539 Tumor Growth Inhibition (TGI)
  • Dosing frequency and duration of dose administration
  • Dosing route (intravenous, intratracheal, continuous infusion, intraperitoneal, intratumoral, oral gavage, topical, intramuscular, subcutaneous, intranasal, using cutting-edge micro-injection techniques and pump-controlled IV injection)
  • SF-539 tumor immunohistochemistry
  • Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
  • Blood chemistry analysis
  • Toxicity and survival (optional: performing a broad health observation program)
  • Gross necropsies and histopathology
  • Positive control group employing cyclophosphamide, at a dosage of 50 mg/kg administered by intramuscular injection to the control group daily for the study duration
  • Lipid distribution and metabolic assays
  • Imaging studies: Fluorescence-based whole body imaging, MRI

Get Instant Quote for
SF-539 Xenograft Model